-
Innovation Ranking
NewInnovation Ranking – L Brands Inc
Bath & Body Works Inc ((Bath & Body) formerly L Brands Inc, is a specialty retailer, operating both physical and online stores. The company’s product portfolio comprises women’s intimate and other apparel, body and bath products, personal care, and beauty products. It also offers lingerie, cosmetics, fragrances, lotions, shower gels, accessories, and soaps. Bath & Body markets products under the Bath and Body Works brand name. It merchandises products through company-operated retail stores, international franchises, licenses, websites, and wholesale partners....
-
Innovation Ranking
NewInnovation Ranking – L&T Technology Services Ltd
L&T Technology Services Ltd (L&T Technology), a subsidiary of Larsen & Toubro Ltd, is a provider of digital engineering, development and consultancy services. The company provides product, manufacturing and operating engineering services in the fields of mechanical, manufacturing automation, security, software development, smart factory, wearable IOT and embedded systems. Its service offerings include software and hardware product design and development, maintenance, testing and validations; agile supply chain; integrated content management; security monitoring; industrial AI and plant engineering; among others. L&T...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Romyelocel-L in Chemotherapy Induced Neutropenia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Romyelocel-L in Chemotherapy Induced Neutropenia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Romyelocel-L in Chemotherapy Induced Neutropenia Drug Details: Romyelocel L (CLT-008) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – L And J-HZ in Herpes Zoster (Shingles)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - L And J-HZ in Herpes Zoster (Shingles) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. L And J-HZ in Herpes Zoster (Shingles) Drug Details:...
-
Product Insights
Alpha L-Iduronidase – Drugs In Development, 2023
Global Markets Direct’s Alpha L-Iduronidase provides in depth analysis on Alpha L-Iduronidase targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha L-Iduronidase targeted therapeutics development and features...
-
Product Insights
Integrin Alpha L – Drugs In Development, 2023
Global Markets Direct’s Integrin Alpha L provides in depth analysis on Integrin Alpha L targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Alpha L targeted therapeutics...
-
Product Insights
Aromatic L Amino Acid Decarboxylase – Drugs In Development, 2023
Global Markets Direct’s Aromatic L Amino Acid Decarboxylase provides in depth analysis on Aromatic L Amino Acid Decarboxylase targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Aromatic...
-
Product Insights
Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency – Drugs In Development, 2023
Global Markets Direct’s, ‘Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency - Drugs In Development, 2023’, provides an overview of the Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency pipeline landscape. The report provides comprehensive information on the therapeutics under development for Aromatic l-Amino Acid Decarboxylase (AADC) Deficiency, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rexlemestrocel-L in Left Ventricular Dysfunction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rexlemestrocel-L in Left Ventricular Dysfunction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rexlemestrocel-L in Left Ventricular Dysfunction Drug Details: Rexlemestrocel-L is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rexlemestrocel-L in Hypoplastic Left Heart Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rexlemestrocel-L in Hypoplastic Left Heart Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rexlemestrocel-L in Hypoplastic Left Heart Syndrome Drug Details: Rexlemestrocel-L is...